Idacta-mab INT-001 represents an promising clinical strategy for combating selected hematologic cancers. The antigen-binding protein shows an distinct mechanism of function, mainly targeting CD38, an cell-surface https://mediajx.com/story27754013/idacta-mab-int-001-a-novel-immunoglobulin-during-progression